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Abstract
Disturbances in intracellular calcium homeostasis are likely prominent and causative factors leading to neuronal cell death
in Alzheimer’s disease (AD). Familial AD (FAD) is early-onset and exhibits autosomal dominant inheritance. FAD-linked
mutations have been found in the genes encoding the presenilins and amyloid precursor protein (APP). Several studies have
shown that mutated presenilin proteins can directly affect calcium release from intracellular stores independently of Ab
production. Although less well established, there is also evidence that APP may directly modulate intracellular calcium
homeostasis. Here, we directly examined whether overexpression of FAD-linked APP mutants alters intracellular calcium
dynamics. In contrast to previous studies, we found that overexpression of mutant APP has no effects on basal cytosolic
calcium, ER calcium store size or agonist-induced calcium release and subsequent entry. Thus, we conclude that mutated
APP associated with FAD has no direct effect on intracellular calcium homeostasis independently of Ab production.
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Introduction
Alzheimer’s disease (AD) is a progressive neurological disorder
characterized by deterioration of cognitive abilities. AD is the most
common cause of dementia in the western world, affecting one in
ten individuals over 65 and nearly 50% of all persons over the age
of 85 [1,2]. According to the predominant amyloid cascade
hypothesis, AD pathogenesis is associated with a series of
molecular events which leads to the extracellular deposition and
aggregation of specific proteolytic fragments of APP. These
aggregated protein fragments constitute the core of extracellular
senile amyloid plaques, a pathologic hallmark of AD.
In normal physiology, APP is cleaved by a series of enzymes,
called secretases, generating proteolytic fragments of various
lengths. The principal cleavage event is by a-secretase, which
generates a large soluble ectodomain (APPs) that is secreted into
the extracellular space and a C-terminal fragment (C83) that
remains in the membrane [3]. In an alternate processing pathway,
holo-APP can be cleaved by b-secretase, resulting in the
production of a secreted ectodomain and the membrane-
associated C99 fragment [3]. Subsequent cleavage of C99 by c-
secretase produces the neurotoxic Ab peptide and an intracellular
domain (AICD) that is released from the membrane into the
cytosol. There are two major forms of the Ab peptide that differ in
length by 2 residues, Ab40 and Ab42. The Ab42 peptide is more
prone to aggregation and is considered to be more cytotoxic than
the shorter Ab species [4].
Most cases of AD are sporadic and late-onset, but rare forms of
familial AD (FAD) are early-onset and exhibit autosomal-dominant
inheritance. The majority of FAD cases are linked to mutations in the
presenilin (PS) genes 1 and 2 [5]. Presenilins constitute the catalytic
core of c-secretase, and PS mutations lead to relative overproduction
of Ab42 [6,7,8,9]. FAD-linked mutations have also been found in
APP, and depending on the mutation result in increased b-secretase
processing, increased Ab42/Ab40 ratio, increased propensity of Ab to
form fibrils, or decreased proteolytic clearance of Ab peptides
[10,11,12,13,14,15,16,17,18,19,20].
While it is clear that APP-derived fragments are involved in a
proximal step in the pathogenesis of AD, the exact mechanism of
neuronal loss in not known. Also, clinical symptoms do not correlate
well with amyloid plaque load, suggesting that a certain level of
neuronal dysfunction precedes gross architectural changes in AD
brain [21,22]. Calcium dyshomeostasis has been implicated as a
major contributor to neuronal cell death in AD [23]. Calcium
dynamics regulate Ab production, and Ab peptides/fibrils directly
affect multiple aspects of calcium homeostasis [24]. There is strong
evidence that mutated presenilin proteins can directly modulate
calcium release from intracellular stores independently of Ab
production [25,26,27], and may also form calcium permeable
channels in the endoplasmic reticulum [28]. Similarly, several studies
have suggested that APP may directly modulate calcium homeostasis
independently of Ab production [29,30,31]. However, a systematic
study of the effects of FAD-associated APP mutants on intracellular
calcium homeostasis has not been reported.
Here, we show that overexpression of FAD-linked APP mutants
has no effect on basal cytosolic calcium concentration, ER calcium
store size, or agonist-induced calcium release and subsequent
entry. These results indicate that mutant APP likely does not
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e11992contribute mechanistically to alterations in calcium homeostasis in
AD independently of Ab production.
Results
Expression of Different FAD-linked APP Mutants in PC12
Cells
For our studies, we focused on six different well-characterized
FAD-linked APP mutants that affect b-secretase cleavage,
fibrillization, and c-secretase cleavage (Figure 1A). The Swedish
double mutant makes APP a more favored substrate for b-
secretase shunting full-length APP down the amyloidogenic
processing pathway [10,11]. The London, Indiana, and V717L
mutations favor production of Ab42 by the c-secretase
[12,13,14,15,16]. The Flemish and Arctic APP mutations increase
the propensity for fibrillization and decrease proteolytic clearance
of Ab peptides [17,18,19,20].
Immunoblot analysis of PC12 cells overexpressing wild-type and
mutant APP revealed two bands with approximate molecular
weight of 110–120 kDa corresponding to immature and mature
forms of the holoprotein (Figure 1B). As APP is trafficked
through the secretory pathway, a series of glycosylation events
occur leading to a mature, or fully glycosylated, protein with
slower mobility on SDS-PAGE. An immunoblot for a/b-tubulin is
shown as a loading control (Figure 1C).
ER Calcium Release, Receptor-operated Calcium Entry,
and ER Calcium Store Size Are Not Affected by
FAD-linked Mutant APP
Calcium release from ER-resident inositol 1,4,5-trisphosphate
receptors (IP3Rs) has been proposed to be a critical mediator of
calcium dyshomeostasis in AD [25,26,27]. To determine whether
mutant APP expression affects IP3R-mediated calcium release, we
measured the response of PC12 cells to the purinergic agonist
UTP, which selectively activates phospholipase C-coupled P2Y
receptors [32]. PC12 cells were co-transfected with yellow
fluorescent protein (YFP) and one of the following: empty vector
control, wild-type APP, or one of six FAD-linked APP mutants. To
selectively examine IP3R activity and exclude the contribution of
calcium entry from the plasma membrane, UTP stimulation was
done in calcium free media. As indicated in the representative
fura-2 calcium traces in Figure 2A, addition of UTP induces a
robust calcium release from the ER into the cytosol in calcium-free
media. Peak calcium release in response to UTP did not differ
between control cells expressing empty vector, cells expressing
wild-type APP, and cells expressing APP mutants (Figure 2B).
Depletion of ER calcium stores by agonist stimulation triggers
store/receptor-operated calcium entry (SOC/ROC) through chan-
nels in the plasma membrane [33]. Entry through these channels has
been proposed to be compromised in fibroblasts expressing mutant
presenilins [34]. To determine the effect of FAD-linked APP mutants
on receptor-operated calcium entry, we waited until cytosolic calcium
levels reached baseline following UTP stimulation in calcium-free
medium and replaced the bath solution with calcium-replete
medium. As shown in Figure 2C, receptor-operated calcium entry
did not differ significantly between control cellsexpressing YFP alone,
cellsexpressingwild-typeAPP,andcellsexpressinganyofthesixAPP
mutants tested.
Next, we wanted to determine the effect of FAD-linked mutant
APP on ER calcium store size. To directly measure ER calcium
content, we utilized ER compartmentalized mag-fura-2 [35,36,37].
As shown in Figure 2D, ER calcium store size did not differ
between control cells, wild-type APP-expressing cells, and any of the
six APP mutants tested.
Agonist-Induced Calcium Release Is Not Affected by
FAD-linked Mutant APP
Mutant presenilins directly modulate calcium release from ER
stores [25,26,27]. To address whether mutant APP has similar
effects, we monitored the response of PC12 cells to two different
doses of UTP. As shown in the representative traces in Figure 3A,
addition of subsaturating (10 mM) and saturating (100 mM) doses
of UTP resulted in transient increases in cytosolic calcium. There
was no difference in the percent of cells that responded to the
subsaturating dose (Figure 3B), indicating that there were no
significant differences in sensitivity to agonist-induced calcium
release. There were also no differences observed in peak calcium
release induced by either dose between control, wild-type APP,
and the six mutant APP-expressing cells (Figure 3C). By
analyzing baseline calcium levels in each condition, we were also
Figure 1. Expression of wild-type APP and different FAD-linked APP mutants in PC12 cells. (A) Schematic diagram depicting the C-
terminal portion of APP with secretase cleavage sites indicated in red and locations of FAD-linked mutations marked with asterisks. The
transmembrane region is shaded in yellow. The epitope for the anti-Ab 1–10 antibody (Millipore catalogue # 07-592) is indicated. Specific amino acid
substitutions for each mutation are shown with residue numbering corresponding to APP770. (B) Overexpression of APP constructs in PC12 cells.
Mock cells were co-transfected with YFP and empty vector. (C) Immunoblot for a/b-tubulin to demonstrate equal loading.
doi:10.1371/journal.pone.0011992.g001
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cells expressing wild-type APP or FAD-linked mutant APP
(Figure 3D).
Discussion
The results of these studies indicate that FAD-linked APP
mutants do not directly affect calcium homeostasis independently
of Ab production, at least in this model system. Several studies
have shown that overexpression of wild-type APP or FAD-linked
mutant APP leads to an increase in basal cytosolic calcium
concentration and an increase in ER store size. Rojas and
colleagues demonstrated that neurons derived from mice possess-
ing three copies of the APP gene have increased resting cytosolic
calcium concentration and altered responses to glutamatergic and
nicotinic agonists and that these effects could be partially restored
by APP knockdown [29]. Cortical neurons from the triple-
transgenic (3xTg-AD) mouse model of AD were also shown to
have elevated resting cytosolic calcium [30]. Overexpression of the
Swedish APP mutant alone was sufficient to cause the same effect.
In these studies, cells were taken from young animals prior to
plaque development, suggesting that the changes observed
represent proximal events in the disease model. In cells from the
3xTg-AD mice, calcium entry as well as release from intracellular
stores both contributed to elevated cytosolic calcium levels [30].
It has been shown that agonist-induced calcium release from
intracellular stores is disrupted in fibroblasts from APP null mice
[31]. This effect is related to a decrease in ER store size and can be
rescued by APP constructs containing the APP intracellular
domain (AICD), suggesting that this peptide fragment is involved
in regulating intracellular calcium stores [31]. Subsequent studies
showed that the loss of AICD was associated with decreased levels
of ATP, perhaps impairing ER calcium uptake via the sarco-
endoplasmic reticulum calcium ATPase [38]. Other studies have
shown that wild-type APP is not directly involved in modulating
calcium stores but does mediate the increase in store size that is
seen with certain PS mutants and PS deficiency [39]. The effect of
PS knockdown on store size was exacerbated in cells expressing the
FAD-linked APP mutant V717I, and this effect correlated with
increased levels of C99 in these cells [39].
Figure 2. ER calcium release, store-operated entry, and store size are not affected by overexpression of APP mutants. (A)
Representative single cell traces of cytosolic [Ca
2+] in control cells (black) and cells expressing APP with the Swedish mutation (red). (B) Peak calcium
release in response to 100 mM UTP in calcium-free medium. The total number of single cells imaged for each condition is indicated above the error
bar. All cells were co-transfected with either empty vector or APP and yellow fluorescent protein (YFP) at a 4:1 ratio. WT, wild-type; Swe, Swedish; Fle,
Flemish; Arc, Arctic; Lon, London; Ind, Indiana. (C) Store-operated calcium entry following addition of calcium-replete medium in control and APP-
transfected cells for each of the APP constructs tested. These results are from continuous imaging of the same coverslips used for the calcium release
experiments shown in (A). (D) ER store size in control and APP-transfected cells for each of the APP constructs tested. For all experiments, error bars
represent standard error of the mean. There was no statistical significance between control and APP expressing cells (p.0.05 for all conditions).
doi:10.1371/journal.pone.0011992.g002
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directly alter calcium signaling when overexpressed in PC12 cells.
T h e s er e s u l t ss u g g e s tt h a tad i f f e r e n tm e c h a n i s mm u s te x i s tf o rt h e
perturbations in intracellular calcium that are observed in forms of
FAD that are linked to mutations in APP.Most likely, these effects are
mediated directly by Ab and not the APP holoprotein. Furthermore,
our results promote the hypothesis that the disruption in calcium
signaling seen with PS mutants is independent of the role for PS in
APP cleavage, and may instead reflect a general role for PS in the
maintenance of intracellular calcium homeostasis.
Methods
Cell Lines
PC12 rat pheochromocytoma cells were purchased from
ATCC. They were cultured in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% fetal bovine serum, 5% horse
serum, 100 U/ml penicillin, 100 mg/ml streptomycin.
Generation of APP Mutants
Point mutations in human APP695 (kindly provided by Dr. Hui
Zheng, Ph.D., Baylor College of Medicine) were accomplished
with the QuickChange Site-directed Mutagenesis Kit (Stratagene,
La Jolla, CA) according to manufacturer’s instructions. Forward
primers were as follows:
Swedish 59-GGAGATCTCTGAAGTGAACCTGGATGCA-
GAATTCC-39;
Flemish 59-CAAAAATTGGTGTTCTTTGGAGAAGATGT-
GGG-39;
Arctic 59-GGTGTTCTTTGCAGGAGATGTGGGTTCAA-
AC-39;
London 59-CATAGCGACAGTGATCATCATCACCTTG-
GTGATGC-39;
Indiana 59-CATAGCGACAGTGATCTTCATCACCTTG-
GTGATGC-39;
V717L 59-CATAGCGACAGTGATCCTCATCACCTTGG-
TGATGC-39.
The reverse primers were the exact reverse complement.
Calcium Imaging
Calcium measurements were performed as previously described
[40]. PC12 cells were cultured on 25 mm coverslips overnight,
and were co-transfected with APP and yellow fluorescent protein
(YFP) at a 4:1 ratio. Under these conditions, we have found that all
YFP-positive cells express both proteins [41]. For all experiments,
transfection efficiency as determined by fluorescence microscopy
was greater than 50%. Similar results were obtained by imaging
APP-GFP fusion proteins (data not shown). For measurement of
cytosolic calcium, cells were loaded with fura-2 as described
elsewhere [40] for 30 minutes at 25uC. For ER calcium
Figure 3. Agonist-induced calcium entry is not affected by overexpression of FAD-linked APP mutants. (A) Representative single cell
traces of cytosolic [Ca
2+] in cells expressing YFP alone (control) or APP with the Swedish mutation (red) upon addition of 10 mM and 100 mM UTP. (B)
Percentage of cells that responded to 10 mM UTP for each condition. (C) Quantification of peak calcium release induced by UTP. (D) Resting (basal)
cytosolic calcium concentration in control and APP-transfected cells for each of the APP constructs tested. Error bars represent standard error of the
mean. There was no statistical significance between control and APP expressing cells (p.0.05 for all conditions).
doi:10.1371/journal.pone.0011992.g003
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minutes at 37uC followed by a 60-minute incubation at 37uCi n
dye-free extracellular medium (107 mM NaCl, 7.2 mM KCl,
1.2 mM MgCl2, 1 mM CaCl2,11.5 mM glucose, 0.1% bovine
serum albumin, and 20 mM HEPES 7.2). Coverslips were
transferred to the microscope and the plasma membrane was
subsequently permeabilized by a brief exposure to 0.01% saponin
to release cytoplasmic dye before exchanging the solution with
intracellular solution (135 mM KCl, 3 mM MgATP, 2 mM
MgCl, 0.4 mM CaCl2, 1 mM EGTA, and 20 mM HEPES 7.1)
as described [35]. All fields were imaged randomly, and all YFP-
positive cells in a given field were imaged and quantified in the
data analysis. The number of cells analyzed is indicated above
each data point. Fura-2/mag-fura-2 and YFP images were
acquired every 3 seconds during acquisition on a Nikon TE2000
inverted microscope using a Nikon 60X oil immersion SuperFluor
objective with a 1.3 numerical aperture. All imaging was
performed at 25uC. Images were captured with a Roper Scientific
CoolSNAP HQ monochrome camera. Rapid filter changes for
ratiometric imaging were computer controlled via a Ludl
MAC6000 rapid filter wheel and changer and MetaFluor data
acquisition and analysis software. Raw data was acquired with
MetaFluor, analyzed in Excel, and graphed in Sigma Plot.
Statistical Analysis
All experiments were performed a minimum of three times and
presented as the mean 6 standard error. Single cell traces from
each coverslip were pooled and averaged for each data point.
Total number of single cell traces is indicated over each bar.
Statistical comparisons from the pooled data were performed
between groups using the student’s t test. Statistical significance
was considered at p values ,0.05.
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